Completed

Phase Not Applicable
Age: 13Years +
All Genders
ID00001115

A Pilot Study to Determine the Effect of Acyclovir Treatment for Herpes Simplex Virus (HSV) Infection on Peripheral Blood HIV Viral Load.

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2016-10-31

75

Participants Needed

15

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Part A: To evaluate the impact of HSV suppression with acyclovir ( ACV ) on HIV burden in patients with asymptomatic HSV infection and at high risk for HSV reactivation. Part B: To characterize the change in plasma HIV RNA levels and other measures of HIV burden during and after a 10 day course of ACV treatment for acute HSV infection. Approximately 70% of patients infected with HIV are concurrently infected with HSV. There is new evidence to suggest that HSV may act as a co-factor in HIV disease progression. This study will attempt to determine if the upregulation of HIV RNA that occurs during symptomatic HSV reactivation also occurs during asymptomatic HSV reactivation and if suppression of HSV will result in decreased levels of HIV RNA. There is a need to determine the patterns of association between HSV and HIV.

CONDITIONS

Official Title

The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood

Who Can Participate

Age: 13Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

Inclusion Criteria

Patients must have:

Parts A and B:

  • Documented HIV infection.
  • Patients >= 18 years of age must be willing and able to give informed consent and patients < 18 years must have written consent from a parent or guardian.

Part A:

  • CD4+ T count < 250 cells/mm3 within 1 month prior to study entry.
  • Documented antibodies to HSV any time prior to study.
  • History of HSV outbreak in past 2 to 12 months.
  • Former Part B patients who have completed the 12 week follow up may enter Part A after at least a 4-week washout.

Part B:

  • Documented CD4+ T count < 250 cells/mm3 anytime prior to study entry.
  • Oral, genital or anorectal lesions with a vesiculopustular component.
  • Presumptive diagnosis of HSV.
  • Former part A patients may enter part B after a 4-week washout.

Exclusion Criteria

Patients with any of the following prior conditions are excluded:

  • Documented or suspected HSV within 2 months prior to study entry.
  • History of infection with an acyclovir resistant HSV strain.
  • History of disseminated HSV.
  • History of treatment for acute CMV or MAC disease.
  • History of poor medication or clinic visit compliance.

Prior Medication:

Excluded:

  • Use of acyclovir, famciclovir, foscarnet, ganciclovir, valacyclovir or cidofovir for any reason within one month prior to study entry. [AS PER AMENDMENT 1/21/97: Use of antiherpes agents, both FDA-approved and investigational, including bis-POM, PMEA, lobucavir, acyclovir, etc.]
  • Initiation or modification of antiretroviral therapy, immunomodulators, or any kind of vaccination within 2 months prior to study entry.
  • Treatment for acute medical condition within 4 weeks prior to study entry.
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

Trial Site Locations

Total: 15 locations

1

AIDS Research Ctr

Palo Alto, California, United States, 94304

Status Unknown

2

Harbor-UCLA Med Ctr

Torrance, California, United States, 90502

Status Unknown

3

Yale Univ School of Medicine / AIDS Program

New Haven, Connecticut, United States, 06510

Status Unknown

4

North Broward Hosp District

Fort Lauderdale, Florida, United States, 33316

Status Unknown

5

Univ of Miami / Jackson Memorial Hosp

Miami, Florida, United States, 331361094

Status Unknown

6

Univ of Illinois - Chicago

Chicago, Illinois, United States, 60612

Status Unknown

7

Univ of Illinois Chicago / Howard Brown Hlth Ctr

Chicago, Illinois, United States, 60612

Status Unknown

8

Johns Hopkins Univ

Baltimore, Maryland, United States, 21205

Status Unknown

9

SUNY Brooklyn / SUNY Health Sciences Ctr at Brooklyn

Brooklyn, New York, United States, 11203

Status Unknown

10

Community Research Initiative on AIDS

New York, New York, United States, 10001

Status Unknown

11

NYU - Bellevue Hosp

New York, New York, United States, 10016

Status Unknown

12

New York Med College / Westchester County Med Ctr

Valhalla, New York, United States, 10595

Status Unknown

13

Research and Education Group

Portland, Oregon, United States, 97210

Status Unknown

14

Univ of Pennsylvania Med Ctr

Philadelphia, Pennsylvania, United States, 19104

Status Unknown

15

Brown Univ / The Miriam Hosp

Providence, Rhode Island, United States, 02906

Status Unknown

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

N/A

Model

N/A

Primary Purpose

TREATMENT

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here